CSI Market
Sign In | Register

C4 Therapeutics Inc (CCCC) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CCCC Annual Cash Flow →
Quarterly cash flow trends provide additional context on C4 Therapeutics Inc's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-48.76
Depreciation & amortization0.70
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue12.04
Impairment of Long-Lived Assets Held-for-use0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation5.71
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Operating Lease Right Of Use Asset Amortization Expense1.44
Increase Decrease In Operating Lease Liability-1.54
Income taxes0.00
Unrealized Gain (Loss) on Investments0.00
Increase (Decrease) in Accounts Receivable-1.07
Increase (Decrease) in Accounts Payable0.26
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.47
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets1.54
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net1.28
Payments for (Proceeds from) Other Operating Activities-3.68
Discontinued operations0.00
Net Cash flow from Operating Activities-31.52
Investing Activities
Capital Expenditures-0.10
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities113.08
Payments to Acquire Marketable Securities-111.64
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities1.34
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock34.13
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.06
Other net0.00
Payments For Vested Stock Option Settlement-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents78.05
Restricted Cash And Cash Equivalents-3.44
Proceeds From Issuance Of Long Term Debt And Warrant-
Proceeds From Issuance Of Follow On Offering-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities34.19
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-31.62
Total Cash Flow4.01
4 historic quarters locked

Sign in to unlock the full C4 Therapeutics Inc cash flow history.

Sign In Create Free Account

About C4 Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-055494

Figures are derived from filed reports and may be restated. Historical data is subject to revision.